SiSaf Ltd
Mahfuja Jannat Bulu is a Senior Molecular Biologist at SiSaf Ltd, with expertise in evaluating genetic engineering and gene therapy outcomes through in vitro and in vivo experiments. Previously, at King's College London, Mahfuja completed a PhD in Cancer and Pharmaceutical Science, focusing on advanced cell culture techniques, molecular biology methods, and gene editing. Mahfuja also holds an MSc in Biochemistry and Molecular Biology from Kingston University, an MPhil from the University of Dhaka, and has extensive research experience, including roles as a Chemistry Analyst and Biochemist. Accumulating substantial laboratory and research experience over nearly two decades, Mahfuja has developed a strong foundation in biochemistry, molecular biology, and cell biology techniques.
This person is not in any offices
SiSaf Ltd
SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.